-transparent.png){kind=logo}
Oxaprozin, an anti-inflammatory agent with a half-life of 50 hours, was compared in regard to efficacy and tolerance with sulindac in a 12-week double-blind parallel treatment trial of rheumatoid arthritis. Oxaprozin was given as a single morning daily dose of 1200 mg, sulindac was given as 200 mg twice daily. Analysis of the results from the 20 patients (10 in each group) who completed the trial indicated that both drugs produced statistically significant improvement in morning stiffness, walking speed and the Ritchie index, but only sulindac produced significant improvement in hand function. Neither drug was associated with significant side-effects.
Related Publications
R Zuccollo, and
M J Mackinnon, and
K M Fraser, and
S M Hall, and
D G Palmer
January 1978,
Current medical research and opinion,
R Zuccollo, and
M J Mackinnon, and
K M Fraser, and
S M Hall, and
D G Palmer
January 1979,
Current medical research and opinion,
R Zuccollo, and
M J Mackinnon, and
K M Fraser, and
S M Hall, and
D G Palmer
July 1981,
The New Zealand medical journal,
R Zuccollo, and
M J Mackinnon, and
K M Fraser, and
S M Hall, and
D G Palmer
January 1980,
Scandinavian journal of rheumatology. Supplement,
R Zuccollo, and
M J Mackinnon, and
K M Fraser, and
S M Hall, and
D G Palmer
January 1979,
The Journal of international medical research,
R Zuccollo, and
M J Mackinnon, and
K M Fraser, and
S M Hall, and
D G Palmer
November 1974,
Annals of the rheumatic diseases,
R Zuccollo, and
M J Mackinnon, and
K M Fraser, and
S M Hall, and
D G Palmer
January 1981,
Terapevticheskii arkhiv,
R Zuccollo, and
M J Mackinnon, and
K M Fraser, and
S M Hall, and
D G Palmer
May 1969,
Annals of the rheumatic diseases,
R Zuccollo, and
M J Mackinnon, and
K M Fraser, and
S M Hall, and
D G Palmer
February 1973,
The Practitioner,
R Zuccollo, and
M J Mackinnon, and
K M Fraser, and
S M Hall, and
D G Palmer
January 1978,
Scandinavian journal of rheumatology. Supplement,
